Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 9/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.47 |
| ▸ | FAP | Q12884 | 2/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.47 |
| ▸ | FNTA | P49354 | 3/20 | 0.45 |
| ▸ | FNTB | P49356 | 3/20 | 0.45 |
| ▸ | GRB2 | P62993 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052866 | 0.91 | GRB2 (0.53) | XIAPDPP4DPP8DPP7FAP | |
| SCHEMBL29575720 | 0.88 | XIAP (0.50) | XIAPFNTAFNTBGRB2LMNA | |
| SCHEMBL29870992 | 0.88 | XIAP (0.55) | XIAPDPP4DPP8DPP7FAP | |
| SCHEMBL29352327 | 0.88 | XIAP (0.55) | XIAPDPP4DPP8DPP7FAP | |
| SCHEMBL30239685 | 0.87 | XIAP (0.47) | XIAPGRB2 | |
| SCHEMBL29573785 | 0.87 | XIAP (0.54) | XIAPDPP4DPP8DPP7FAP | |
| SCHEMBL30052397 | 0.86 | XIAP (0.48) | XIAPFNTAFNTBGRB2LMNA | |
| SCHEMBL30599189 | 0.86 | XIAP (0.53) | XIAPDPP4DPP8DPP7FAP | |
| SCHEMBL31747054 | 0.85 | XIAP (0.57) | XIAPDPP4DPP8DPP7FAP | |
| SCHEMBL31130225 | 0.85 | XIAP (0.54) | XIAPDPP4DPP8DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-11576414-B1 | Food compositions containing added honey proteins | SHIGETA RONALD TAKEO (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | XIAP 4043/4885DPP4 43/4885DPP8 41/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | XIAP 2121/4885DPP4 73/4885DPP8 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.